United States (US) Viral Vectors and Plasmid DNA Market (2025-2031) | Value, Share, Size & Revenue, Competitive Landscape, Industry, Growth, Analysis, Forecast, Segmentation, Outlook, Companies, Trends

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Viral Vectors and Plasmid DNA Market - Industry Life Cycle

3.4 United States (US) Viral Vectors and Plasmid DNA Market - Porter's Five Forces

3.5 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume Share, By Product, 2021 & 2031F

3.6 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume Share, By Application, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing research and development activities in gene therapy and genetic engineering

4.2.2 Growing demand for biopharmaceuticals and personalized medicine

4.2.3 Technological advancements in viral vector and plasmid DNA production and delivery systems

4.3 Market Restraints

4.3.1 Stringent regulatory requirements for gene therapy products

4.3.2 High manufacturing costs associated with viral vectors and plasmid DNA

4.3.3 Limited efficiency and specificity of current gene delivery systems

6.1 United States (US) Viral Vectors and Plasmid DNA Market, By Product

6.1.1 Overview and Analysis

6.1.2 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Product, 2021- 2031F

6.1.3 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Plasmid DNA, 2021- 2031F

6.1.4 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Viral Vectors, 2021- 2031F

6.1.5 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Non-viral Vectors, 2021- 2031F

6.2 United States (US) Viral Vectors and Plasmid DNA Market, By Application

6.2.1 Overview and Analysis

6.2.2 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Cancers, 2021- 2031F

6.2.3 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Inherited Disorders, 2021- 2031F

6.2.4 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Viral Infections, 2021- 2031F

6.2.5 United States (US) Viral Vectors and Plasmid DNA Market Revenues & Volume, By Others, 2021- 2031F

7.1 United States (US) Viral Vectors and Plasmid DNA Market Export to Major Countries

7.2 United States (US) Viral Vectors and Plasmid DNA Market Imports from Major Countries

8.1 Research and development investment in gene therapy technologies

8.2 Number of clinical trials utilizing viral vectors and plasmid DNA

8.3 Adoption rate of gene therapy products in the healthcare industry

9.1 United States (US) Viral Vectors and Plasmid DNA Market Opportunity Assessment, By Product, 2021 & 2031F

9.2 United States (US) Viral Vectors and Plasmid DNA Market Opportunity Assessment, By Application, 2021 & 2031F

10.1 United States (US) Viral Vectors and Plasmid DNA Market Revenue Share, By Companies, 2024

10.2 United States (US) Viral Vectors and Plasmid DNA Market Competitive Benchmarking, By Operating and Technical Parameters